Forum Financial Management LP Acquires 147 Shares of Zoetis Inc. $ZTS

Forum Financial Management LP grew its holdings in Zoetis Inc. (NYSE:ZTS) by 4.2% during the 2nd quarter, Holdings Channel reports. The firm owned 3,662 shares of the company’s stock after purchasing an additional 147 shares during the period. Forum Financial Management LP’s holdings in Zoetis were worth $571,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of ZTS. Nova Wealth Management Inc. bought a new position in shares of Zoetis in the 1st quarter valued at about $25,000. 1248 Management LLC bought a new position in Zoetis during the 1st quarter worth approximately $27,000. Saudi Central Bank bought a new position in Zoetis during the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC boosted its stake in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after acquiring an additional 88 shares during the last quarter. Finally, REAP Financial Group LLC boosted its stake in Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after acquiring an additional 131 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $146.14 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The company has a market capitalization of $64.77 billion, a P/E ratio of 25.15, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90. The company’s 50 day moving average price is $148.18 and its two-hundred day moving average price is $153.50. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $184.40.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period last year, the company posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ZTS. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler lifted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research note on Friday. Finally, UBS Group reduced their price objective on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research note on Monday. Four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $195.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.